Lexicon Pharmaceuticals Inc. (LXRX)

7.96
0.10 1.27
NASDAQ : Health Technology
Prev Close 7.86
Open 7.86
Day Low/High 7.86 / 8.23
52 Wk Low/High 7.80 / 18.00
Volume 602.30K
Avg Volume 616.50K
Exchange NASDAQ
Shares Outstanding 105.59M
Market Cap 975.63M
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week of LXRX February 2018 Options Trading

Investors in Lexicon Pharmaceuticals, Inc. saw new options become available this week, for the February 2018 expiration.

First Week Of July 2018 Options Trading For Lexicon Pharmaceuticals (LXRX)

First Week Of July 2018 Options Trading For Lexicon Pharmaceuticals (LXRX)

Investors in Lexicon Pharmaceuticals, Inc. saw new options become available this week, for the July 2018 expiration.

Short Interest Declines 13.8% For LXRX

Short Interest Declines 13.8% For LXRX

The most recent short interest data has been released for the 10/31/2017 settlement date, which shows a 2,150,673 share decrease in total short interest for Lexicon Pharmaceuticals, Inc. , to 13,435,509, a decrease of 13.80% since 10/13/2017.

First Week of LXRX December 15th Options Trading

Investors in Lexicon Pharmaceuticals, Inc. saw new options begin trading this week, for the December 15th expiration.

European Commission Approves XERMELO® (Telotristat Ethyl) For The Treatment Of Carcinoid Syndrome Diarrhea In Combination With Somatostatin Analog Therapy

European Commission Approves XERMELO® (Telotristat Ethyl) For The Treatment Of Carcinoid Syndrome Diarrhea In Combination With Somatostatin Analog Therapy

First-in-Class Oral Tryptophan Hydroxylase Inhibitor that Sustains Improvement of Carcinoid Syndrome Diarrhea in Adults Inadequately Controlled by Somatostatin Analogs

LXRX: Insiders vs. Shorts

The most recent short interest data was recently released for the 08/31/2017 settlement date, and Lexicon Pharmaceuticals, Inc. is one of the most shorted stocks of the Russell 3000, based on 31.32 "days to cover" versus the median component at 6.19.

Biotech Mailbag: Buy Dip in T2 Biosystems?

Biotech Mailbag: Buy Dip in T2 Biosystems?

Plus, what's going on with Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals Reports Positive Pooled Continuous Glucose Monitoring Data From Pivotal Phase 3 InTandem1 And InTandem2 Studies Of Sotagliflozin

Lexicon Pharmaceuticals Reports Positive Pooled Continuous Glucose Monitoring Data From Pivotal Phase 3 InTandem1 And InTandem2 Studies Of Sotagliflozin

- Patients on sotagliflozin 200 mg spent 1.3 hours longer in target glucose range per day than placebo

Interesting LXRX Put And Call Options For September 15th

Interesting LXRX Put And Call Options For September 15th

Investors in Lexicon Pharmaceuticals, Inc. saw new options begin trading today, for the September 15th expiration.

Lexicon Collaborator Ipsen Receives Positive CHMP Opinion For Xermelo® (Telotristat Ethyl)

Lexicon Collaborator Ipsen Receives Positive CHMP Opinion For Xermelo® (Telotristat Ethyl)

First -in-Class Oral Tryptophan Hydroxylase Inhibitor to be Considered for Approval in Europe for the Treatment of Carcinoid Syndrome Diarrhea in Combination with Somatostatin Analog Therapy

Interesting LXRX Put And Call Options For August 18th

Investors in Lexicon Pharmaceuticals, Inc. saw new options become available this week, for the August 18th expiration.

TheStreet Quant Rating: D (Sell)